Why the study?
Does macitentan reduce morbidity and mortality events in patients with symptomatic pulmonary arterial hypertension?
Does macitentan reduce morbidity and mortality events in patients with symptomatic pulmonary arterial hypertension?
Macitentan is a once-daily oral dual endothelin receptor antagonist that reduces morbidity and mortality events in patients with symptomatic pulmonary arterial hypertension.
May support macitentan for composite event reduction in symptomatic PAH; leaves open mortality benefit and need for confirmatory trials.
Macitentan is a novel dual endothelin receptor antagonist recently approved for the treatment of symptomatic pulmonary arterial hypertension (PAH). Compared to other endothelin receptor antagonists, in vitro and in vivo studies have demonstrated that macitentan has improved tissue targeting, a longer duration of action and an improved safety profile. Macitentan is available as a once daily oral medication and has been well tolerated in clinical trials. The recently published Study with an Endothelin Receptor Antagonist in PAH to Improve cliNical Outcomes (SERAPHIN), which was the first event-driven trial ever done in PAH, also demonstrated the benefit of macitentan on reducing the likelihood of a composite endpoint of morbidity and mortality events without a significant difference in mortality.
No takes yet. Share an insight, caveat, or question.
DuBrock et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: